---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000030"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:34:16.393697+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman

## Summary
- Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.
- Jost Fisher steps down as Interim CEO but continues as chairman and on audit/comp committees.
- Bancroft base salary $425k, eligible for annual bonus target 50% of salary.
- Bancroft receives 59,034 stock options and 177,103 RSUs under new Inducement Plan (1M shares reserved).
- Prior role: GM of Therapeutics at Revance Therapeutics until its acquisition by Crown Labs in Feb 2024.

## SEC filing metadata
- accession: 0001837607-25-000030
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/0001837607-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/aeon-20250419x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000030
- JSON: https://secwatch.observer/filing/0001837607-25-000030.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000030.txt

## Key facts
- Executive change
  Jost Fisher changed role as Interim President and Chief Executive Officer at AEON Biopharma, Inc..
  - Action: stepped down as Interim President and Chief Executive Officer
  - Role: Interim President and Chief Executive Officer
  source text: Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/0001837607-25-000030-index.htm
- Executive change
  Robert Bancroft was appointed as Chief Executive Officer, President and Principal Executive Officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: Chief Executive Officer, President and Principal Executive Officer
  source text: On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/0001837607-25-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.